Rachael Lester
Known title: Chief Business OfficerCIK: 0002094324
Associated companies
Transaction History
| CTMX | ▲ Buy | Grant | 20,000 | $0 | 2/2/2026 | View on chart |
| CTMX | ▲ Buy | Grant | 20,000 | $0 | 2/2/2026 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
CTMX to Present at September Investor Conferences
CytomX Therapeutics announced it will present at upcoming investor conferences in September, a routine corporate event where biotech firms typically discuss pipeline progress and business strategy with institutional investors and analysts. The company's shares have been trading in a notably wide range over the past year, between $1.90 and $8.21, reflecting the volatility common among smaller biotechnology companies working to advance their drug candidates through development. The September conference presentations could provide updated information on CytomX's ongoing programs and corporate priorities.
CTMX to Present at September Investor Conferences. CytomX Therapeutics announced it will present at upcoming investor conferences in September, a routine corporate event where biotech firms typically discuss pipeline progress and business strategy with institutional investors and analysts. The company's shares have been trading in a notably wide range over the past year, between $1.90 and $8.21, reflecting the volatility common among smaller biotechnology companies working to advance their drug candidates through development. The September conference presentations could provide updated information on CytomX's ongoing programs and corporate priorities.